Tobacco Treatment for Smoking Cessation

Recruiting in Palo Alto (17 mi)

+18 other locations

Jamie S. Ostroff, PhD - MSK Psychologist

Overseen byJamie Ostroff, PhD

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 4

Waitlist Available

Sponsor: Memorial Sloan Kettering Cancer Center

No Placebo Group

Prior Safety Data

Trial Summary

What is the purpose of this trial?This study is to help determine the most effective type or combination of treatments to offer patients seeking lung cancer screening who are smokers to help them reduce the number of cigarettes they smoke, or quit smoking. The investigators long term goal is to increase the benefits of lung cancer screening by providing a blue print of best practices for screening sites to deliver tobacco treatment to their patients who are smokers, in a way that does not add burden to screening site staff and increases the chances of patients quitting smoking.

Eligibility Criteria

This trial is for smokers aged 50-80 who are getting lung cancer screening at sites with certain qualifications. They must smoke currently, be reachable by phone, and speak English or Spanish. Smokers can't join if they've had a recent heart attack, unstable angina, or used tobacco treatments in the past month.

Inclusion Criteria

I am between 50 and 80 years old.

Patient must have at least a 20 pack-year history of smoking

I have smoked cigarettes in the last 30 days.

+7 more

Exclusion Criteria

I cannot use nicotine replacement therapy due to a recent heart issue.

I am a smoker using cessation aids or services within the last month.

Participant Groups

The study tests different ways to help smokers quit as part of lung cancer screening programs. It includes message framing techniques, nicotine lozenges, motivational interviewing (MI), nicotine replacement therapy (NRT), and saliva sampling to find the best method without overburdening staff.

4Treatment groups

Experimental Treatment

Group I: Nicotine Replacement Therapy (NRT) Patch (Yes vs. No)Experimental Treatment2 Interventions

Participants will receive 6 weeks of NRT patch with dosing dependent upon reported baseline cigarettes per day and written instructions to use the patch daily starting on date they mutually agreed upon with their site coordinator. Participants who smoke fewer than 10 cigarettes per day will receive 4-weeks of the 14mg patch (2 boxes), and 2-weeks of the 7mg patch (1 box). Those who smoke 10 or more cigarettes per day will receive 4-weeks of the 21mg patch (2 boxes) and 2-weeks of the 14mg patch (1 box). Participants will receive their study medications from their site coordinator on the day of their screening appointment or via mail from Arrowhead Promotion \& Fulfillment.

Group II: NRT Lozenge (Yes vs. No)Experimental Treatment2 Interventions

Participants will receive will receive 6 packs of NRT 2mg lozenge and written instructions to use the lozenge PRN to help manage acute nicotine withdrawal. Participants will be instructed to use the NRT lozenges no more than every 1-2 hours as needed. Participants will receive their study medications from their site coordinator on the day of their screening appointment or via mail from Arrowhead Promotion \& Fulfillment.

Group III: Motivational Interviewing( MI) (Yes vs. No)Experimental Treatment2 Interventions

Participants will receive two motivational informed cessation sessions; the first delivered face to faceor via telephone by the SC during the patient's initial lung cancer screening visit or during the shared decision making discussion or within about 1 week following their screening visit, and the second session delivered by telephone by the SC approximately 4 to 8 weeks after the first MI session.

Group IV: Message Framing (Gain vs. Loss)Experimental Treatment2 Interventions

Overall, a robust body of health communication literature demonstrates that gain-framed messages may be more effective than loss-framed or non-framed (neutral) messages for encouraging smoking cessation. In other words, quitting messages that promote smoking cessation are more persuasive if they emphasize the benefits of quitting (gain-framed) rather than the risks (loss-framed) of persistent smoking (25, 26). Included with the written communication of their LDCT-LCS results, participants will receive a printed individualized quitting message that emphasizes either the benefits of quitting (gain-framed) or the risks of continuing to smoke (loss-framed).